在复发性耐火性多发性骨髓瘤中使用talquetamab:多机构的现实研究
Samer Al Hadidi1,2, Aniko Szabo3, Bhavesh Mohan Lal4
1Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA. Samer.AlHadidi@UTSouthwestern.edu.
Blood cancer journal
|November 7, 2025
概括
塔尔基塔马布在复发性/耐药性多发性骨髓瘤 (RRMM) 患者中显示出显著的疗效,达到73%的整体应答率. 这些真实世界的数据证实了它的有效性,但强调了需要管理像减肥和感染这样的毒性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 塔尔基塔马布是一种GPRC5DxCD3双特异性抗体,用于复发性/耐火性多发性髓瘤 (RRMM).
- RRMM患者往往只有有限的治疗选择,尤其是在多次先前治疗后.
研究的目的:
- 评估talquetamab在重度预先治疗的RRMM患者中的实际疗效和安全性.
- 评估与talquetamab治疗相关的应答率,生存结果和不良事件.
主要方法:
- 对114名RRMM患者的多中心回顾性分析,这些患者接受了talquetamab治疗.
- 收集关于患者特征,先前治疗,治疗反应,生存和不良事件的数据.
主要成果:
- 总体响应率 (ORR) 为73%,其中26%是完全响应 (CR).
- 无进展生存 (PFS) 的中位数为10个月;6个月的PFS和整体生存 (OS) 率分别为56%和86%.
- 常见的不良事件包括细胞因子释放综合征 (CRS; 54%),感染 (27%) 和神经毒性 (9.8%);还观察到显著的体重减轻.
结论:
- 塔尔基塔马布在严重预先治疗的RRMM人群中显示出显著的疗效.
- 毒性管理,包括感染和减肥,对于最佳的患者护理至关重要.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Therapeutic Drug Monitoring: Affecting Factors
189
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
189
Therapeutic Drug Monitoring: Overview and Classification
282
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
282


